Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study (Abstract )
Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature (Abstract )
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera (Abstract )
Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning (Abstract )
Second cancers in MPN: Survival analysis from an international study (Abstract )
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases (Abstract )
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis (Abstract )
NanoR: A user-friendly R package to analyze and compare nanopore sequencing data (Abstract )
Second primary malignancies in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study on 2233 patients (Abstract )
Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models (Abstract )
Atomic-Level Mechanism of Pre-mRNA Splicing in Health and Disease (Abstract )
A continuous-time Markov model approach for modeling myelodysplastic syndromes progression from cross-sectional data (Abstract )
Combined loss of function of two different loci of miR-15/16 drives the pathogenesis of acute myeloid leukemia (Abstract )
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms (Abstract )
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (Abstract )
Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome (Abstract )
Multicenter Next-Generation Sequencing Studies Between Theory and Practice: Harmonization of Data Analysis Using Real-World Myelodysplastic Syndrome Data (Abstract )
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS (Abstract )
Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome (Abstract )
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups (Abstract )
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms (Abstract )
Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis (Abstract )
Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies (Abstract )
Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis (Abstract )
Genomic Analysis of Hematopoietic Stem Cell at the Single-Cell Level: Optimization of Cell Fixation and Whole Genome Amplification (WGA) Protocol (Abstract )
Preclinical study for treatment of hypospadias by advanced therapy medicinal products (Abstract )
Bone marrow-specific loss of ABI1 induces myeloproliferative neoplasm with features resembling human myelofibrosis (Abstract )
Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation (Abstract )
Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients (Abstract )
Activating somatic and germline TERT promoter variants in myeloid malignancies (Abstract )
Genomic integrity and mitochondrial metabolism defects in Warsaw syndrome cells: a comparison with Fanconi anemia (Abstract )
A novel mutation of indoleamine 2,3-dioxygenase 1 causes a rapid proteasomal degradation and compromises protein function (Abstract )
Identification of two independent clones underlying the co-existence of myelodysplastic syndrome with excess of blasts type 2 and isolated 5q- and smouldering multiple myeloma (Abstract )
Cytogenetic/mutation profile of chronic lymphocytic leukemia/malignant melanoma collision tumors of the skin (Abstract )
High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement (Abstract )
Identification and monitoring of atypical PML/RARA fusion transcripts in acute promyelocytic leukemia (Abstract )
Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS) (Abstract )
Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes (Abstract )
Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy (Abstract )
Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes (Abstract )
Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia (Abstract )
Longitudinal detection of DNMT3AR882Htranscripts in patients with acute myeloid leukemia (Abstract )
Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy (Abstract )
The poly(ADP-ribose) polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by NF-κB activation (Abstract )